$9.5 is absurd, throwing cold water on the NVS license and VPHM deal that should be boosting IMGN this morning. They are obviously supporting either a short that wants out, or a long that wants in IMO. Can someone find a link to that garbage report?
Is anyone going to the annual meeting? We need someone to represent the retail shareholders and ask some tough questions. Someone on the IV board called the meeting Bagels and BS, so I am not going to make a long trip for that, but maybe we have someone local?
I too am getting the feeling that "something is going on." Anyone who has an understanding of the world of oncology was not too surprised by the 901 result. They continue to extend licenses to multiple Partners (who clearly are savvy Pharma execs still with faith in the technology). They also have an active research program with very interesting compounds in much more assailable disease states; moreover, T-DM1 will only increase is sales over the next 2-3 years. No question there.
The drop in price seems underserving to me.